Publications by authors named "Rosalind Walker"
Article Synopsis
- * In a Phase II clinical trial, 27 patients received entinostat followed by nivolumab, resulting in an objective response rate of 11% and a median response duration of over 10 months, although the primary endpoint for overall effectiveness was not reached.
- * The combination treatment led to significant immune profile changes, including increased dendritic cell activity and enhanced inflammatory response, suggesting potential for improving treatment strategies in PDA despite
is a member of the Debaryomycetaceae family in the order Saccharomycetales. Here, we present the genome sequence of UCD805, which was isolated from soil in Dublin, Ireland. This genome is 12.
View Article and Find Full Text PDFArticle Synopsis
- Advanced colorectal cancer (CRC) patients typically have MMR-proficient tumors that don't respond well to traditional PD1 blockade therapy; this study explored the use of combined DNMT and HDAC inhibitors to improve treatment effectiveness.
- In a trial involving 27 patients, the combination treatment was safe but showed limited clinical benefits, with only one patient experiencing a significant, lasting response.
- Common side effects included anemia, lymphopenia, nausea, and vomiting, indicating that while the treatment was tolerable, more research is needed to understand how to boost its effectiveness in altering the tumor microenvironment.
We previously reported CHFR methylation in a subset of colorectal cancer (CRC; ∼30%) with high concordance with microsatellite instability (MSI). We also showed that CHFR methylation predicted for sensitivity to docetaxel, whereas the MSI-high phenotypes were sensitive to gemcitabine. We hypothesized that this subset of patients with CRC would be selectively sensitive to gemcitabine and docetaxel.
View Article and Find Full Text PDFABT-751 is an orally bioavailable sulfonamide with antimitotic properties. A nonrandomized phase 1 dose-escalation study of ABT-751 in combination with CAPIRI (capecitabine and irinotecan) and bevacizumab was conducted to define the maximum tolerated dose, dose-limiting toxicity (DLT), and pharmacokinetics in patients with advanced colorectal cancer. Patients were treated with ABT-751 daily for 7 days (alone) and then began 21-day cycles of treatment with ABT-751 daily and capecitabine twice daily for 14 days plus irinotecan on day 1 intravenously.
View Article and Find Full Text PDF